期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CD52抗原的研究进展及其抗体在临床中的应用 被引量：3

下载PDF
导出
摘要 人类CD52属于一个未命名的短链GPI锚定糖蛋白家族,其基因定位于人类1号染色体(1p36.1),分子量为25～29KD.广泛分布于淋巴细胞、单核细胞等造血细胞上和雄性生殖系统中的某些细胞表面,在造血干/祖细胞表面没有表达.由于①其具有在淋巴细胞和很多造血系统恶性肿瘤细胞上的高密度分布;②其分子交联化可引起一系列信号传导,从而导致细胞因子分泌,细胞增殖、生长抑制及凋亡;③其分子在细胞表面排列整齐、密度大,与抗体结合后结合补体的能力受抗体亚类影响较小等特点,抗CD52单克隆抗体(CAMPATH-1系列)已经被广泛地用于临床治疗.CD52分子自身直接的生物学功能目前还知之甚少,被人们利用的大部分都与其GPI锚定蛋白的特性相关.除CAMPATH-1系列抗CD52单抗以外,HI186因识别表位不同,其在生物学功能和临床应用上的差别值得关注.
作者 屈浩 廖晓龙
机构地区 [ 中国医学科学院血液学研究所
出处 《国外医学（免疫学分册）》 2005年第6期369-373,共5页 Foreign Medical Sciences(Section of Immunology Foreign Medical Sciences)
关键词 CD52 CAMPATH-1 GPI 锚定蛋白 药用抗体
分类号 R392.1 [医药卫生—免疫学]
  • 相关文献

参考文献20

  • 1Quigley MM,Bethel KJ,Sharpe RW,et al.CD52 expression in hairy cell leukemia[J].Am J Hematol,2003,74(4):227-230.
  • 2Hale G,Cobbold S,Novitzky N,et al.On behalf of CAMPATH users,CAMPATH-1 antibodies in stem cell transplantation[J].Cytotherapy,2001,3:145-164.
  • 3Albitar M,Do KA,Johnson MM,et al.Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies[J].Cancer.2004,101(5):999-1008.
  • 4Rowan W,Tite J,Topley P,et al.Cross-linking of the CAMPATH-1 antigen(CD52) mediates growth inhibition in human B- and T-lymphoma cell lines,and subsequent emergence of CD52-deficient cells[J].Immunology,1998,95:427-436.
  • 5Hederer RA,Guntermann C,Miller N,et al.CD45 tyrosine phosphatase regulates Campath-1H(CD52)-induced TCR-dependent signal transduction in human T cells[J].Int Immunol,2000,12:505-516.
  • 6Nuckel H,Frey UH,Roth A,et al.Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity[J].Eur J Pharmacol.,2005,514(2-3):217-224.
  • 7Dyer MJS,Hale G.Effects of CAMPATH-1H in vivo in patients with lymphoid malignancies:influence of antibody isotype[J].Blood,1989,73:1431-1439.
  • 8Dearden CE,Matutes E,Cazin B,et al.High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H[J].Blood,2001,98:1721-1726.
  • 9Keating MJ,Flinn I,Jain V,et al.Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine:results of a large international study[J].Blood,2002,99:3554-3561.
  • 10Lundin J,Kimby E,Bjorkholm M,et al.Phase Ⅱ trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (CAMPATH-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (BCLL)[J].Blood,2002,100:768-773.

同被引文献37

  • 1冯琛(综述),蒋敬庭(审阅).免疫检查点分子联合CAR-T细胞治疗实体肿瘤研究进展[J].中国肿瘤生物治疗杂志,2022,29(4):349-353. 被引量：1
  • 2王玉刚,沈倍奋.CD20抗原及治疗性抗CD20抗体[J].中国肿瘤生物治疗杂志,2005,12(1):76-79. 被引量：10
  • 3Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia[J]. Blood, 2009, 113(25): 6330-6337.
  • 4Maury S, Huguet F, Leguay T, et al.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia [J].Haematologica, 95(2): 324-328.
  • 5Bachanova V, Sandhu K, Yohe S, et al. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia[J]. Blood, 2011, 117(19): 5261-5263.
  • 6Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphobtastic leukemia[J].Cancer, 2006, 106(7): 1569-1580.
  • 7Thomas DA, O' Brien S, Cortes JE, et al.Long-term outcome for de novo or minimally treated Burkitt-type lymphoma/leukemia(BL/B-ALL)after therapy with Hyper- CVAD and rituximab[J].ASH Annual Meeting Abstracts, 2010, 116: 1781.
  • 8Deborah A Thomas, Susan O'Brien, Stefan Faderl, et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-Lineage acutelymphoblastic leukemia[J].J Clin Oncol, 2010, 28(24): 3880-3889.
  • 9Hoelzer D, Huettmann A, Kaul F, et al.lmmunochemotherapy with rituximab improves molecular CR rate and outcome In CD20+B-lineage standard and high risk patients, results of 263 CD20+patients studied prospectively in GMALL study 07/2003[J].ASH Annual Meeting Abstracts, 2010, 116: 170.
  • 10Chevallier P, Pigneux A, Robillard N, et al.Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series[J]. Leukemia Research, 2012, 36(3): 311-315.

引证文献3

二级引证文献4

国外医学（免疫学分册）
2005年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部